You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
国药疫苗首发第三期临床结果 保护率逾70%
阿思达克 05-27 09:29
国际医学期刊《美国医学会杂志》(JAMA)昨日(26日)刊登国药集团中国生物发表的《两种新型冠状病毒灭活疫苗对成人COVID-19感染的保护效力评价》。研究结果显示,中国生物两款新冠灭活疫苗两针接种後14天,能产生高滴度抗体,形成有效保护,且全人群中和抗体阳转率达99%以上。「WIV04」疫苗组保护效力为72.8%,「HB02」疫苗组的保护效力为78.1%。

报告根据中国生物新冠灭活疫苗三期临床试验结果,总结分析中国生物所属北京生物制品研究所(BIBP)、武汉生物制品研究所(WIBP)新冠灭活疫苗的有效性、安全性等三期临床试验结果,为全球首个正式发表的新冠灭活疫苗三期临床试验结果,亦为中国新冠疫苗三期临床试验结果的首次发表。

国药疫苗第三期临床试验於去年7月中至12月底在阿联酋及巴林进行,共4万多人参与,全为18岁或以上人士,平均年龄约36岁,两剂接种时间相隔21日。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account